Supernus Pharmaceuticals ROA 2011-2024 | SUPN

Current and historical return on assets (ROA) values for Supernus Pharmaceuticals (SUPN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Supernus Pharmaceuticals ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2024-03-31 $-0.02B $1.30B -1.24%
2023-12-31 $0.00B $1.28B 0.07%
2023-09-30 $0.03B $1.29B 1.65%
2023-06-30 $0.04B $1.29B 2.65%
2023-03-31 $0.05B $1.79B 3.02%
2022-12-31 $0.06B $1.70B 3.63%
2022-09-30 $0.04B $1.69B 2.26%
2022-06-30 $0.06B $1.70B 3.53%
2022-03-31 $0.07B $1.64B 4.58%
2021-12-31 $0.05B $1.69B 3.42%
2021-09-30 $0.08B $1.56B 5.41%
2021-06-30 $0.10B $1.57B 6.63%
2021-03-31 $0.11B $1.51B 7.45%
2020-12-31 $0.13B $1.50B 8.99%
2020-09-30 $0.13B $1.51B 9.72%
2020-06-30 $0.12B $1.49B 9.62%
2020-03-31 $0.12B $1.19B 10.35%
2019-12-31 $0.11B $1.16B 10.38%
2019-09-30 $0.11B $1.11B 10.16%
2019-06-30 $0.11B $1.06B 10.53%
2019-03-31 $0.10B $1.03B 10.90%
2018-12-31 $0.11B $0.98B 12.41%
2018-09-30 $0.10B $0.92B 13.09%
2018-06-30 $0.09B $0.85B 13.99%
2018-03-31 $0.07B $0.83B 14.75%
2017-12-31 $0.06B $0.42B 15.44%
2017-09-30 $0.06B $0.39B 16.73%
2017-06-30 $0.10B $0.35B 32.62%
2017-03-31 $0.10B $0.32B 33.80%
2016-12-31 $0.09B $0.31B 36.11%
2016-09-30 $0.08B $0.29B 37.88%
2016-06-30 $0.03B $0.22B 13.52%
2016-03-31 $0.02B $0.19B 10.23%
2015-12-31 $0.01B $0.19B 8.63%
2015-09-30 $0.01B $0.17B 7.37%
2015-06-30 $0.01B $0.15B 3.60%
2015-03-31 $0.01B $0.14B 4.84%
2014-12-31 $-0.01B $0.14B -9.67%
2014-09-30 $-0.04B $0.13B -34.50%
2014-06-30 $-0.06B $0.09B -55.27%
2014-03-31 $-0.09B $0.10B -76.56%
2013-12-31 $-0.09B $0.11B -81.61%
2013-09-30 $-0.08B $0.12B -77.39%
2013-06-30 $-0.07B $0.13B -77.42%
2013-03-31 $-0.06B $0.08B -68.75%
2012-12-31 $-0.05B $0.09B -66.20%
2012-09-30 $0.05B $0.07B 80.33%
2012-06-30 $0.05B $0.08B 115.25%
2012-03-31 $0.05B $0.04B 218.56%
2011-12-31 $0.05B $0.05B 377.78%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.663B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.040B 6.57
Dr Reddy's Laboratories (RDY) India $13.038B 19.39
BridgeBio Pharma (BBIO) United States $4.901B 0.00
Bausch Health Cos (BHC) Canada $2.746B 2.12
Amphastar Pharmaceuticals (AMPH) United States $1.937B 11.65
Taysha Gene Therapies (TSHA) United States $0.400B 0.00
Personalis (PSNL) United States $0.200B 0.00
Assembly Biosciences (ASMB) United States $0.083B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.023B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00